SCHEMBL11919901

SCHEMBL11919901

Cc1ccc(-c2noc(CSc3nnc(-c4ccncc4)n3-c3ccc(Cl)cc3)n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TP53 P04637 7/20 1.00
NPSR1 Q6W5P4 3/20 0.90
LMNA P02545 2/20 0.84
HTT P42858 2/20 0.84
MEN1 O00255 2/20 0.82
KMT2A Q03164 2/20 0.82
ALDH1A1 P00352 1/20 0.82
TNKS2 Q9H2K2 11/20 0.82
MAPT P10636 5/20 0.80
TNKS O95271 4/20 0.80
CYP3A4 P08684 1/20 0.80
CYP2D6 P10635 1/20 0.80
CYP2C9 P11712 1/20 0.80
SULT2A1 Q06520 1/20 0.80
NR5A1 Q13285 1/20 0.80
AXIN2 Q9Y2T1 1/20 0.80
THRB P10828 3/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
GAA P10253 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11919909 0.91 TP53 (0.84) TP53NPSR1LMNAHTTMEN1
SCHEMBL13048271 0.91 TP53 (0.84) TP53NPSR1LMNAHTTMEN1
SCHEMBL11919903 0.91 TP53 (1.00) TP53NPSR1LMNAHTTMEN1
SCHEMBL13046998 0.90 NPSR1 (0.90) TP53NPSR1LMNAHTTMEN1
SCHEMBL11919979 0.89 NPSR1 (0.87) TP53NPSR1LMNAHTTMEN1
SCHEMBL11919898 0.89 TNKS2 (1.00) TP53NPSR1LMNAMEN1KMT2A
SCHEMBL11919944 0.85 NPSR1 (0.74) TP53NPSR1LMNAHTTMEN1
SCHEMBL11919942 0.85 LMNA (0.78) TP53NPSR1LMNAHTTMEN1
SCHEMBL11920016 0.85 TP53 (0.84) TP53NPSR1LMNAHTTMEN1
SCHEMBL11919907 0.83 NPSR1 (0.72) TP53NPSR1LMNAHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
WO-2010139966-A1 AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS OSLO UNIVERSITY HOSPITAL HF (NO) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 TP53 53/4885NPSR1 4727/4885LMNA 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.